Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861339 | 1.00 | HTT (0.39) | HTTMTNR1APDE5AGAAPDCD1 | |
| SCHEMBL1504120 | 1.00 | HTT (0.39) | HTTMTNR1APDE5AGAAPDCD1 | |
| SCHEMBL1379501 | 0.82 | MTNR1A (0.51) | HTTMTNR1APDE5A | |
| SCHEMBL1379498 | 0.82 | MTNR1A (0.51) | HTTMTNR1APDE5A | |
| SCHEMBL17292437 | 0.80 | LMNA (0.32) | HTT | |
| SCHEMBL17224233 | 0.80 | LMNA (0.32) | HTT | |
| SCHEMBL15591379 | 0.78 | NR1I2 (0.31) | MTNR1A | |
| SCHEMBL20464506 | 0.77 | ALDH1A1 (0.39) | HTTMTNR1AGAA | |
| SCHEMBL15820269 | 0.76 | — | — | |
| SCHEMBL3307631 | 0.76 | GAA (0.53) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4392397-A2 | PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS | AbbVie Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023028558-A2 | PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS | ABBVIE INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20230020952-A1 | MACROCYCLES COMPRISING A 4-AMIDO-2,4-PENTADIENOATE MOIETY FOR THE TREATMENT OF HYPOXIC CANCERS | AARHUS UNIVERSITET (DK) | 2023-01-19 | — | — | US | disclosed |
| WO-2021110968-A1 | MACROCYLCES COMPRISING A 4-AMIDO-2,4-PENTADIENOATE MOIETY FOR THE TREATMENT OF HYPOXIC CANCERS | AARHUS UNIVERSITET (DK) | 2021-06-10 | — | — | WO | disclosed |
| EP-2601177-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2017-10-18 | — | — | EP | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| EP-2223923-A1 | Process for the preparation of a chiral beta aminoacid derivative and intermediates thereof | Esteve Química, S.A. (ES) | 2010-09-01 | — | — | EP | disclosed |
| US-7615549-B2 | Substituted pyrrolidinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-10 | — | — | US | disclosed |
| EP-2061772-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | Curis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2009036051-A1 | BCL-2 INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009036035-A1 | BCL-2 INHIBITORS | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20070032473-A1 | Substituted amides and their use as medicaments | GERLACH KAI | 2007-02-08 | — | — | US | disclosed |
| US-20060142263-A1 | NEW SUBSTITUTED PYRROLIDINONES, THEIR MANUFACTURE AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | HTT 2183/4885MTNR1A 3457/4885PDE5A 3629/4885 |
| US-20230020952-A1 | MACROCYCLES COMPRISING A 4-AMIDO-2,4-PENTADIENOATE MOIETY FOR THE TREATMENT OF HYPOXIC CANCERS | DLD, HIF1A, DPYD | HTT 3052/4885MTNR1A 1900/4885PDE5A 3467/4885 |
| US-20060142263-A1 | NEW SUBSTITUTED PYRROLIDINONES, THEIR MANUFACTURE AND THEIR USE AS MEDICAMENTS | PYCR1, OAT, UROD | HTT 2738/4885MTNR1A 470/4885PDE5A 1171/4885 |
| US-20070032473-A1 | Substituted amides and their use as medicaments | OAT, HLA-B, BCAT2 | HTT 3414/4885MTNR1A 310/4885PDE5A 3429/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | HTT 3192/4885MTNR1A 2899/4885PDE5A 1627/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | HTT 3192/4885MTNR1A 2899/4885PDE5A 1627/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | HTT 3761/4885MTNR1A 3368/4885PDE5A 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.